Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Liabilities and Shareholders Equity (2024 - 2025)

Humacyte has reported Liabilities and Shareholders Equity over the past 2 years, most recently at $116.4 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $116.4 million for Q4 2025, down 15.6% from a year ago — trailing twelve months through Dec 2025 was $509.2 million (down 7.81% YoY), and the annual figure for FY2025 was $116.4 million, down 15.6%.
  • Liabilities and Shareholders Equity for Q4 2025 was $116.4 million at Humacyte, up from $91.5 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for HUMA hit a ceiling of $162.6 million in Q1 2025 and a floor of $91.5 million in Q3 2025.